Sweden · Delayed Price · Currency is SEK BioArctic AB Statistics
Total Valuation
BioArctic AB has a market cap or net worth of SEK 26.21 billion. The enterprise value is 24.21 billion.
| Market Cap | 26.21B |
| Enterprise Value | 24.21B |
Important Dates
The next confirmed earnings date is Thursday, July 23, 2026.
| Earnings Date | Jul 23, 2026 |
| Ex-Dividend Date | May 29, 2026 |
Share Statistics
BioArctic AB has 88.72 million shares outstanding. The number of shares has increased by 0.23% in one year.
| Current Share Class | 74.32M |
| Shares Outstanding | 88.72M |
| Shares Change (YoY) | +0.23% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 32.20% |
| Owned by Institutions (%) | 44.02% |
| Float | 54.40M |
Valuation Ratios
The trailing PE ratio is 123.13 and the forward PE ratio is 278.68. BioArctic AB's PEG ratio is 37.11.
| PE Ratio | 123.13 |
| Forward PE | 278.68 |
| PS Ratio | 22.85 |
| PB Ratio | 11.92 |
| P/TBV Ratio | 11.92 |
| P/FCF Ratio | 21.08 |
| P/OCF Ratio | 20.91 |
| PEG Ratio | 37.11 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 47.48, with an EV/FCF ratio of 19.48.
| EV / Earnings | 113.55 |
| EV / Sales | 21.11 |
| EV / EBITDA | 47.48 |
| EV / EBIT | 48.94 |
| EV / FCF | 19.48 |
Financial Position
The company has a current ratio of 6.54, with a Debt / Equity ratio of 0.02.
| Current Ratio | 6.54 |
| Quick Ratio | 5.12 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.08 |
| Debt / FCF | 0.03 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 10.32% and return on invested capital (ROIC) is 2,051.98%.
| Return on Equity (ROE) | 10.32% |
| Return on Assets (ROA) | 12.88% |
| Return on Invested Capital (ROIC) | 2,051.98% |
| Return on Capital Employed (ROCE) | 21.68% |
| Weighted Average Cost of Capital (WACC) | 0.08% |
| Revenue Per Employee | 8.14M |
| Profits Per Employee | 1.51M |
| Employee Count | 141 |
| Asset Turnover | 0.48 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BioArctic AB has paid 200.49 million in taxes.
| Income Tax | 200.49M |
| Effective Tax Rate | 48.46% |
Stock Price Statistics
The stock price has increased by +48.07% in the last 52 weeks. The beta is -0.76, so BioArctic AB's price volatility has been lower than the market average.
| Beta (5Y) | -0.76 |
| 52-Week Price Change | +48.07% |
| 50-Day Moving Average | 319.69 |
| 200-Day Moving Average | 309.29 |
| Relative Strength Index (RSI) | 43.18 |
| Average Volume (20 Days) | 204,064 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioArctic AB had revenue of SEK 1.15 billion and earned 213.24 million in profits. Earnings per share was 2.40.
| Revenue | 1.15B |
| Gross Profit | 1.08B |
| Operating Income | 494.81M |
| Pretax Income | 413.73M |
| Net Income | 213.24M |
| EBITDA | n/a |
| EBIT | 494.81M |
| Earnings Per Share (EPS) | 2.40 |
Balance Sheet
The company has 2.03 billion in cash and 40.74 million in debt, with a net cash position of 1.99 billion or 22.47 per share.
| Cash & Cash Equivalents | 2.03B |
| Total Debt | 40.74M |
| Net Cash | 1.99B |
| Net Cash Per Share | 22.47 |
| Equity (Book Value) | 2.20B |
| Book Value Per Share | 24.78 |
| Working Capital | 2.20B |
Cash Flow
In the last 12 months, operating cash flow was 1.25 billion and capital expenditures -10.24 million, giving a free cash flow of 1.24 billion.
| Operating Cash Flow | 1.25B |
| Capital Expenditures | -10.24M |
| Depreciation & Amortization | 15.12M |
| Net Borrowing | 890,000 |
| Free Cash Flow | 1.24B |
| FCF Per Share | 14.01 |
Margins
Gross margin is 94.13%, with operating and profit margins of 43.14% and 18.59%.
| Gross Margin | 94.13% |
| Operating Margin | 43.14% |
| Pretax Margin | 36.07% |
| Profit Margin | 18.59% |
| EBITDA Margin | n/a |
| EBIT Margin | 43.14% |
| FCF Margin | 108.36% |
Dividends & Yields
This stock pays an annual dividend of 2.00, which amounts to a dividend yield of 0.70%.
| Dividend Per Share | 2.00 |
| Dividend Yield | 0.70% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -0.23% |
| Shareholder Yield | 0.47% |
| Earnings Yield | 0.81% |
| FCF Yield | 4.74% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for BioArctic AB is 301.40, which is 2.03% higher than the current price. The consensus rating is "Hold".
| Price Target | 301.40 |
| Price Target Difference | 2.03% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 6.76% |
| EPS Growth Forecast (3Y) | -3.74% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |